Addex Provides Update on ADX71149 Phase 2 Epilepsy Study : v

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small...

Related Keywords

Switzerland , Geneva , Genè , United States , American , Swiss , Tim Dyer , Roger Mills , Mike Sinclair , Swiss Exchange , Nasdaq , Janssen Pharmaceuticals Inc , Chief Medical Officer , Janssen Pharmaceuticals , American Depositary Shares , Forward Looking Statements , Private Securities Litigation Reform Act , Addex Therapeutic Annual Report , Addex Therapeutics , Addex Therapeutic , Markets ,